Evaluation of library ranking efficacy in virtual screening

We present the results of a comprehensive study in which we explored how the docking procedure affects the performance of a virtual screening approach. We used four docking engines and applied 10 scoring functions to the top‐ranked docking solutions of seeded databases against six target proteins. The scores of the experimental poses were placed within the total set to assess whether the scoring function required an accurate pose to provide the appropriate rank for the seeded compounds. This method allows a direct comparison of library ranking efficacy. Our results indicate that the LigandFit/Ligscore1 and LigandFit/GOLD docking/scoring combinations, and to a lesser degree FlexX/FlexX, Glide/Ligscore1, DOCK/PMF (Tripos implementation), LigandFit1/Ligscore2 and LigandFit/PMF (Tripos implementation) were able to retrieve the highest number of actives at a 10% fraction of the database when all targets were looked upon collectively. We also show that the scoring functions rank the observed binding modes higher than the inaccurate poses provided that the experimental poses are available. This finding stresses the discriminatory ability of the scoring algorithms, when better poses are available, and suggests that the number of false positives can be lowered with conformers closer to bioactive ones. © 2004 Wiley Periodicals, Inc. J Comput Chem 26: 11–22, 2005

[1]  L. Kuyper,et al.  X-ray Crystallographic Studies of Candida albicans Dihydrofolate Reductase , 1997, The Journal of Biological Chemistry.

[2]  Shaomeng Wang,et al.  How Does Consensus Scoring Work for Virtual Library Screening? An Idealized Computer Experiment , 2001, J. Chem. Inf. Comput. Sci..

[3]  Jeremy R. H. Tame,et al.  Scoring functions: A view from the bench , 1999, J. Comput. Aided Mol. Des..

[4]  M Stahl,et al.  Structure-based library design: molecular modelling merges with combinatorial chemistry. , 2000, Current opinion in chemical biology.

[5]  L. Kuo,et al.  Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. , 1996, The Journal of biological chemistry.

[6]  R. DesJarlais,et al.  An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: crystallographic and pharmacokinetic analysis. , 1994, Biochemistry.

[7]  P. M. Dean,et al.  New Perspectives in Drug Design , 1995 .

[8]  Abby L. Parrill,et al.  Rational drug design : novel methodology and practical applications , 1999 .

[9]  C. Supuran,et al.  Sulfenamido-sulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV. , 1997, Journal of enzyme inhibition.

[10]  Gennady M Verkhivker,et al.  Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. , 1995, Chemistry & biology.

[11]  M. Murcko,et al.  Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. , 1999, Journal of medicinal chemistry.

[12]  D H Kim,et al.  Inhibition of thermolysin with nitrone-bearing substrate analogs: a new type of thermolysin inhibitors. , 1998, Bioorganic & medicinal chemistry letters.

[13]  D K Gehlhaar,et al.  De novo design of enzyme inhibitors by Monte Carlo ligand generation. , 1995, Journal of medicinal chemistry.

[14]  Gerhard Klebe,et al.  Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation. , 2002, Journal of medicinal chemistry.

[15]  W Pangborn,et al.  Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents. , 1998, Journal of medicinal chemistry.

[16]  Joseph R. Luft,et al.  Comparison of ternary crystal complexes of F31 variants of human dihydrofolate reductase with NADPH and a classical antitumor furopyrimidine. , 1998 .

[17]  J. Springer,et al.  Stromelysin‐1: Three‐dimensional structure of the inhibited catalytic domain and of the C‐truncated proenzyme , 1995, Protein science : a publication of the Protein Society.

[18]  D E Tronrud,et al.  Crystallographic structural analysis of phosphoramidates as inhibitors and transition-state analogs of thermolysin. , 1989, European journal of biochemistry.

[19]  G. Maga,et al.  Synthesis, properties, and pharmacokinetic studies of N2-phenylguanine derivatives as inhibitors of herpes simplex virus thymidine kinases. , 1995, Journal of medicinal chemistry.

[20]  Maria Kontoyianni,et al.  Evaluation of docking performance: comparative data on docking algorithms. , 2004, Journal of medicinal chemistry.

[21]  Elaine C. Meng,et al.  Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design. , 1997 .

[22]  D. Christianson,et al.  Fluoroaromatic-fluoroaromatic interactions between inhibitors bound in the crystal lattice of human carbonic anhydrase II. , 2001, Journal of the American Chemical Society.

[23]  W G Hol,et al.  Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. , 2000, Journal of molecular biology.

[24]  B. Matthews,et al.  Binding of hydroxamic acid inhibitors to crystalline thermolysin suggests a pentacoordinate zinc intermediate in catalysis. , 1982, Biochemistry.

[25]  J. Bolin,et al.  Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. I. General features and binding of methotrexate. , 1982, The Journal of biological chemistry.

[26]  David S. Goodsell,et al.  Protein‐Ligand Docking , 2000 .

[27]  K D Watenpaugh,et al.  Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors. , 1995, Journal of medicinal chemistry.

[28]  J L Meek,et al.  Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies. , 1998, Journal of medicinal chemistry.

[29]  M. Dowty,et al.  Design and synthesis of piperazine-based matrix metalloproteinase inhibitors. , 2000, Journal of medicinal chemistry.

[30]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[31]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[32]  Xueliang Fang,et al.  Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.

[33]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[34]  Samantha G. Zeitlin,et al.  Structural analysis of inhibitor binding to human carbonic anhydrase II , 1998, Protein science : a publication of the Protein Society.

[35]  Y. Martin,et al.  A general and fast scoring function for protein-ligand interactions: a simplified potential approach. , 1999, Journal of medicinal chemistry.

[36]  Renxiao Wang,et al.  Comparative evaluation of 11 scoring functions for molecular docking. , 2003, Journal of medicinal chemistry.

[37]  Gerd Folkers,et al.  The structures of thymidine kinase from Herpes simplex virus type 1 in complex with substrates and a substrate analogue , 1997, Protein science : a publication of the Protein Society.

[38]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[39]  D. Rognan,et al.  Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. , 2000, Journal of medicinal chemistry.

[40]  C. Venkatachalam,et al.  LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. , 2003, Journal of molecular graphics & modelling.

[41]  J. Doyon,et al.  The pattern of fluorine substitution affects binding affinity in a small library of fluoroaromatic inhibitors for carbonic anhydrase. , 1999, Organic letters.

[42]  P. Bartlett,et al.  Possible role for water dissociation in the slow binding of phosphorus-containing transition-state-analogue inhibitors of thermolysin. , 1987, Biochemistry.

[43]  L F Kuyper,et al.  X-Ray crystal structures of Candida albicans dihydrofolate reductase: high resolution ternary complexes in which the dihydronicotinamide moiety of NADPH is displaced by an inhibitor. , 2001, Journal of medicinal chemistry.

[44]  Frank Wien,et al.  Exploring the active site of herpes simplex virus type‐1 thymidine kinase by X‐ray crystallography of complexes with aciclovir and other ligands , 1998, Proteins.

[45]  Yonghao Jin,et al.  Inactivation of Thermolysin with N-Chloroacetyl-N-hydroxy-β-L-phenylalanine N-methylamide , 1999 .

[46]  E. Bradley,et al.  Comparing performance of computational tools for combinatorial library design. , 2003, Journal of medicinal chemistry.

[47]  M. Natchus,et al.  Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. , 1999, Journal of medicinal chemistry.

[48]  R Crowther,et al.  X‐ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin , 2001, Protein science : a publication of the Protein Society.

[49]  B R Baker,et al.  Nonclassical antimetabolites. XXVI. Inhibitors of thymidine kinase. II. Inhibition by functionalized 1-alkyluracils. , 1966, Journal of medicinal chemistry.

[50]  H M Holden,et al.  The binding of L-valyl-L-tryptophan to crystalline thermolysin illustrates the mode of interaction of a product of peptide hydrolysis. , 1989, The Journal of biological chemistry.

[51]  M. Natchus,et al.  Design and synthesis of conformationally-constrained MMP inhibitors. , 1998, Bioorganic & medicinal chemistry letters.

[52]  PatrickY.-S. Lam,et al.  Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. , 1994, Science.

[53]  T. Baker,et al.  Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. , 2000, Journal of medicinal chemistry.

[54]  Mark A. Murcko,et al.  Virtual screening : an overview , 1998 .

[55]  Paul A. Rejto,et al.  Reduced Dimensionality in Ligand—Protein Structure Prediction: Covalent Inhibitors of Serine Proteases and Design of Site-Directed Combinatorial Libraries , 1999 .

[56]  H M Holden,et al.  Slow- and fast-binding inhibitors of thermolysin display different modes of binding: crystallographic analysis of extended phosphonamidate transition-state analogues. , 1989, Biochemistry.

[57]  M Rarey,et al.  Detailed analysis of scoring functions for virtual screening. , 2001, Journal of medicinal chemistry.

[58]  J. Powers,et al.  Peptide hydroxamic acids as inhibitors of thermolysin. , 1978, Biochemistry.

[59]  M. Doyle,et al.  Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity. , 1996, Biochemistry.

[60]  R. Clark,et al.  Consensus scoring for ligand/protein interactions. , 2002, Journal of molecular graphics & modelling.